General Information About Childhood Brain and Spinal Cord Tumors
Primary brain tumors are a diverse group of diseases that together constitute the most common solid tumor of childhood. The Central Brain Tumor Registry of the United States (CBTRUS) estimates that approximately 4,300 U.S. children are diagnosed each year.[1]
Brain tumors are classified by histology, but tumor location and extent of spread are also important factors that affect treatment and prognosis. Immunohistochemical analysis, cytogenetic and molecular genetic findings, and measures of proliferative activity are increasingly used in tumor diagnosis and classification.[2]
References
- Ostrom QT, Gittleman H, Farah P, et al.: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15 (Suppl 2): ii1-56, 2013. [PUBMED Abstract]
- Louis DN, Perry A, Reifenberger G, et al.: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131 (6): 803-20, 2016. [PUBMED Abstract]
Type of Childhood Brain and Spinal Cord Tumors
For information about the type of childhood brain and spinal cord tumor and its related PDQ summary, see the table below. If a tumor type is not listed, a corresponding PDQ treatment summary is not available.
| Tumor Type (Based on the 2021 WHO Classification)a | Pathological Subtype (Based on the 2021 WHO Classification)a | Related PDQ Treatment Summary |
|---|---|---|
| CNS = central nervous system; NEC = not elsewhere classified; NOS = not otherwise specified; WHO = World Health Organization. | ||
| aWHO classification adapted from Louis et al.[1] | ||
| Pediatric-type diffuse high-grade gliomas | Diffuse pediatric-type high-grade glioma, H3-wild type and IDH-wild type | Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment |
| Diffuse midline glioma, H3 K27-altered | ||
| Diffuse hemispheric glioma, H3 G34-mutant | ||
| Infant-type hemispheric glioma | ||
| Circumscribed astrocytic gliomas | Pilocytic astrocytoma | Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment |
| High-grade astrocytoma with piloid features | ||
| Subependymal giant cell astrocytoma | ||
| Pleomorphic xanthoastrocytoma | ||
| Choroid glioma | ||
| Astroblastoma, MN1-altered | ||
| Ependymal tumors | Subependymoma | Childhood Ependymoma Treatment |
| Myxopapillary ependymoma | ||
| Supratentorial ependymoma, NOS | ||
| Supratentorial ependymoma, ZFTA fusion–positive | ||
| Supratentorial ependymoma, YAP1 fusion–positive | ||
| Posterior fossa ependymoma, NOS | ||
| Posterior fossa group A (PFA) ependymoma | ||
| Posterior fossa group B (PFB) ependymoma | ||
| Spinal ependymoma, NOS | ||
| Spinal ependymoma, MYCN-amplified | ||
| Pediatric-type diffuse low-grade glioma | Diffuse astrocytoma, MYB- or MYBL1-altered | Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment |
| Angiocentric glioma | ||
| Polymorphous low-grade neuroepithelial tumor of the young | ||
| Diffuse low-grade glioma, MAPK pathway-altered | ||
| Glioneuronal and neuronal tumors | Dysembryoplastic neuroepithelial tumor | Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment |
| Ganglioglioma | ||
| Gangliocytoma | ||
| Desmoplastic infantile ganglioglioma | ||
| Desmoplastic infantile astrocytoma | ||
| Diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters (provisional entity) | ||
| Papillary glioneuronal tumor | ||
| Rosette-forming glioneuronal tumor | ||
| Myxoid glioneuronal tumor | ||
| Diffuse leptomeningeal glioneuronal tumor | ||
| Multinodular and vacuolating neuronal tumor | ||
| Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease) | ||
| Extraventricular neurocytoma | ||
| Cerebellar liponeurocytoma | ||
| Central neurocytoma | ||
| Tumors of the pineal region | Pineoblastoma | Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment |
| Embryonal tumors | Medulloblastoma, WNT-activated | Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment |
| Medulloblastoma, SHH-activated and TP53-mutant; Medulloblastoma, SHH-activated and TP53-wildtype | ||
| Medulloblastoma, non-WNT/non-SHH | ||
| Medulloblastoma, histologically defined | ||
| Desmoplastic nodular medulloblastoma | ||
| Medulloblastoma with extensive nodularity | ||
| Large cell medulloblastoma | ||
| Anaplastic medulloblastoma | ||
| Embryonal tumor with multilayered rosettes, C19MC-altered | ||
| CNS tumor with BCOR internal tandem duplication | ||
| CNS neuroblastoma, FOXR2-activated | ||
| CNS embryonal tumor, NEC/NOS | ||
| Atypical teratoid/rhabdoid tumor | Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment | |
| Germ cell tumors | Germinoma | Childhood Central Nervous System Germ Cell Tumors Treatment |
| Embryonal carcinoma | ||
| Yolk sac tumor | ||
| Choriocarcinoma | ||
| Mature teratoma | ||
| Immature teratoma | ||
| Teratoma with somatic-type malignancy | ||
| Mixed germ cell tumor | ||
| Tumors of the sellar region | Adamantinomatous craniopharyngioma | Childhood Craniopharyngioma Treatment |
| Papillary craniopharyngioma | ||
References
- Louis DN, Perry A, Wesseling P, et al.: The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23 (8): 1231-1251, 2021. [PUBMED Abstract]
Latest Updates to This Summary (12/19/2023)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
This summary was comprehensively reviewed and extensively revised.
This summary was renamed from Childhood Brain and Spinal Cord Tumors Treatment Overview.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® Cancer Information for Health Professionals pages.
Conditions covered
Reproduced for free educational use under the licence shown above. WhiteCoat Pro is not affiliated with or endorsed by the authors, the publisher or the issuing organisation. Always check the original document for the current version.